Home / Business News

Business News

Fulcrum Acquires Global Rights to Losmapimod, a Potential Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a biotechnology company focused on discovering and developing therapies to rebalance gene expression, today announced an exclusive worldwide license agreement with GlaxoSmithKline (GSK) for development and commercialization of the investigational drug losmapimod. Fulcrum intends to advance losmapimod into a Phase 2b trial in the rare and …

Read More »

FSD Pharma to Acquire Prismic Pharmaceuticals for $17.5 Million

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company”) and Prismic Pharmaceuticals Inc. (“Prismic”), a US-based specialty R&D pharmaceutical company, announced today that they have entered into a securities exchange agreement dated April 22, 2019 (the “Agreement”) pursuant to which FSD Pharma has agreed …

Read More »

Lilly and Avidity Biosciences Enter License and Research Collaboration in Immunology and Other Indications

INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications. The companies will utilize Avidity’s technology platform to progress new therapeutic approaches toward …

Read More »

OncoSec and Duke University School of Medicine Collaborate in HER2+ Breast Cancer Evaluating TAVO with Plasmid DNA Vaccines

SAN DIEGO and PENNINGTON, N.J., April 17, 2019 /PRNewswire/ — OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary TAVOPLUS (enhanced IL-12 DNA-plasmid) …

Read More »

Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Retinal Diseases and Changes Name to IVERIC bio

NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the Company is changing its name to IVERIC bio, Inc. In conjunction with the corporate name …

Read More »

Gilead and Insitro Collaborate for Discovery and Development of Novel Therapies for Nonalcoholic Steatohepatitis

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the three-year collaboration, insitro’s proprietary platform will be utilized …

Read More »

Catalent to Acquire Gene Therapy Leader Paragon Bioservices for $1.2 Billion

SOMERSET, N.J. and BALTIMORE, April 15, 2019 /PRNewswire/ — Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they …

Read More »

Fibrocell and Castle Creek Pharmaceuticals Collaborate for Development and Commercialization of FCX-007 Gene Therapy

EXTON, Pa., April 15, 2019 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (Nasdaq: FCSC), a cell and gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the completion of a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene …

Read More »

Dr. Reddy’s Laboratories Announces Acquisition of ANDA Portfolio

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the …

Read More »

Gilead and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

FOSTER CITY, Calif. & BAGSVÆRD, Denmark–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a proof of …

Read More »